Due to limited donor availability, high comorbidities, and cost issues, allogeneic hematopoietic stem cell transplant is not universally accessible. The aim of this study was to conduct a cost-effectiveness analysis of haploidentical vs matched unrelated transplant. This retrospective study included patients with hematological malignancies older than 55 years who underwent haploidentical or matched unrelated transplant between 2011 and 2013 in Marseille. The incremental costeffectiveness ratio has been calculated using the mean overall survival and the mean transplant costs. Costs were calculated using a micro-costing strategy from the hospital perspective and a time horizon at 2 years. Haploidentical transplant was considered an innovative procedure and matched unrelated transplant as the reference. Probabilistic and sensitivity analyses were performed on the incremental cost-effectiveness ratio. During inclusion, 29 patients underwent haploidentical transplant and 63 matched unrelated transplant. In haploidentical and matched unrelated transplant, the mean overall survival was 19.4 (1.6) months and 15.1 (1.2) months (p = 0.06), respectively, and the mean cost was 98,304 (40,872) € and 151,373 (65,742) € (p < 0.01), respectively. The incremental cost-effectiveness ratio was assessed to −148,485 (−1,265,550; −64,368) € per life year gained. Among older patients suffering from hematological malignancies, haploidentical transplant seemed in our analysis to be costeffective compared with matched unrelated transplant.
Introduction
Over the past decades, the number of allogeneic hematopoietic stem cell transplant (allo-HSCT) performed all over the world has increased [1, 2] despite its high procedural costs and limited access to all patients [3] [4] [5] [6] .
Optimal allo-HSCT uses matched related donors (MRDs). However, the probabilities of finding such a donor for a given patient are below 30% [7] leading to the development of grafts from unrelated donors (UDs) [8, 9] .
Nevertheless, identifying UD requires a register search, which lengthens the delay from diagnosis to treatment. Also, the probability of finding a suitable UD in such databases, varies greatly according to the patient's ethnicity [7, 10, 11] .
Thus, alternative donors, such as unit cord blood donors or haploidentical related donors (HRDs) have been considered [12] .
Indeed, considering HRD, the probability of finding a suitable donor are over 95%, which make grafts more available [13] . Furthermore, several studies with younger patients show comparable overall survival (OS) and less chronic or acute Graft Versus Host Disease (GVHD-c or GVHD-a) in HRD transplant (HRD-SCT) compared with UD transplant (UD-SCT) [14] [15] [16] . HRD-SCT also shortens time between diagnosis and transplant [17] : this major prognosis factor has been historically demonstrated in chronic myeloid leukemia [18] [19] [20] .
In a study conducted in Marseille (France), with patients older than 55 and suffering from various hematological malignancies, Blaise et al. [21] compared survival according to three donor's type (MRD, UD, and HRD). They found a higher OS and progression-free survival (PFS) with post-transplant cyclophosphamide HRD-SCT compared with UD-SCT.
Among the economic burden of malignant blood disorders across Europe [22] , the high cost of allo-HSCT depends on the donor type; UD-SCT being more expensive than MRD-SCT [23] [24] [25] [26] . Among children, Matthes-Martin et al. [27] found UD-SCT more expensive than HRD-SCT after multivariate analysis.
In the current context of healthcare costs monitoring, the interest of economic evaluation lies in its ability to grant an optimal allocation of rarefying resources. Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the relative costs and outcomes (effects) of two alternatives of action. To perform a cost-effectiveness study of HRD-SCT, we had to choose the relevant standard of care for comparison. For patients without a MRD, the issue of HRD-SCT or MUD-SCT is currently under debate [28, 29] . HRD-SCT could not be considered as alternative to MRD-SCT when a MRD donor is available.
Regarding its potentially lower cost, and with at least a comparable survival, HRD-SCT in adults could be a costeffective alternative to UD-SCT. However, to our knowledge, no economic evaluation has yet been performed to compare HRD-SCT and UD-SCT in adults. Our study aimed to perform a HRD-SCT vs UD-SCT CEA in adults using patients from a previous study [21] .
Methods
A retrospective study was conducted on patients older than 55 with hematological malignancies, who underwent HRD-SCT or UD-SCT between 2011 and 2013 in Marseille (France). The patients characteristics, donors information, and transplants procedures have been previously described [21] . Informed consent was obtained from all patients included in this study approved by our institutional review board (Comité d'Orientation Stratégique de l'Institut Paoli Calmettes).
CEA design
The CEA was conducted from the societal perspective and considered direct medical costs. The time horizon was fixed at 2 years. The primary and secondary effectiveness criteria were the OS and the PFS, respectively.
Resources use
Costs evaluation used a micro-costing method with detailed observations of resources consumed by patients. The monetary valorization was based on 2014 French prices.
Costs were divided into three phases: pre-transplantation, initial hospitalization, and follow-up. The CEA based on the PFS excluded the costs of relapse.
The pre-transplantation phase included preparatory consultations, recipient testing, and graft procurement (GP). Recipient testing included laboratory tests, Human Leucocyte Antigen typing, imaging, and specialist consultations. GP included the donor search, donor testing and harvesting, and grafts transport. The initial hospitalization phase included the full hospitalization in the transplant unit or in the intensive care unit (ICU), medication and blood products (BPs) administration. Information on total body irradiation, medication used in conditioning regimens, parenteral nutrition, and treatment of GVHD or infections, was collected from hospital records. The follow-up phase included the full hospitalization, day ward attendance, outpatient consultations, imaging, laboratory test in the outpatient department, and BP administration. Extracorporeal photopheresis, donor's lymphocyte injections, CD34+ stem cell boost, relapse treatment, and post-acute care were also included.
Costs valorization
The unit costs were mainly calculated using a bottom-up approach. A top down approach was used for the calculation of a few factors unit costs, such as inpatient days in the ICU, or in the non-ICU ward. A mean unit cost for GP was calculated for each donor's type, using 2014 global costs of GP in the hospital. Full hospitalization and day ward attendance costs were assessed calculating a daily cost by ward from 2014 analytical accounting. Daily costs included direct, indirect, and overhead costs. BP costs were separately assessed. Medication costs were separately assessed using 2014 unit prices negotiated by the hospital, only in transplant unit during initial hospitalization.
Extracorporeal photopheresis, total body irradiation, and post-acute care daily costs were obtained using the national scale costs studies [30, 31] . The costs of cryopreservation and cellular sorting for CD34(+) stem cell boost were obtained from detailed analyses performed at the hospital. The unit cost of outpatient consultations was calculated from 2014 analytical accounting. The laboratory testing, imaging, and BP costs were assessed with national tariffs [32] [33] [34] [35] .
Statistical analysis
Mean and median OS and PFS were assessed using Kaplan-Meier estimator. Costs were discounted with a 4% rate [36] . The incremental cost-effectiveness ratios [37] (ICER), assessing effectiveness with OS and PFS, were calculated considering HRD-SCT as innovative and UD-SCT as the reference.
The confidence regions of the ICERs were calculated with the Fieller's method [38] [39] [40] [41] . Sensitivity analyses were conducted using a ±20% rate. Survival curves were compared using log-rank test. Costs and length of stay were compared using Student's t-tests according the result of the Fisher's test of equality of variance between the two groups. Baseline characteristics were compared using chi-squared and Fisher's exact tests. The significance level was set at 0.05.
Results

Patients' and transplantations' baseline characteristics
During the inclusion period, 63 patients underwent UD-SCT and 31 patients underwent HRD-SCT. Two patients were excluded from HRD-SCT group because economic data were incomplete. In average, patients were 61 (4.7) years old in the HRD-SCT group and 64 (3.9) years old in the UD-SCT group (p = 0.01). Patients in the HRD-SCT group had more often non-myelo-ablative conditioning (NMAC) (p < 0.001). Other baseline characteristics were comparable between groups (Table 1) .
Effectiveness
In HRD-SCT group and UD-SCT group, median OS was over 24 months and 23.3 months (log-rank p = 0.058), respectively, and median PFS was over 24 months and 10.3 months (log-rank p = 0.035) (Figs. 1-2), respectively.
Mean OS and PFS were 19.4 (1.6) months and 17.6 (1.8) months in UD-SCT group vs 15.1 (1.2) months and 13.3 (1.2) months in HRD-SCT group, respectively. Both mean OS and mean PFS difference between groups were 4.3 months.
Costs HRD-SCT mean discounted total cost was 98,304 (40,872) € vs 151,373 (65,742) € in UD-SCT (Table 2) . Cost difference between the two groups was 53,069 (11,374) € (p < 0.001).
When excluding the costs incurred during relapse, the costs of HRD-SCT decreased to 89,915 (41,323) € vs 140,137 (59,774) € in UD-SCT. The cost difference was therefore 50,222 (10,891) € (p < 0.001).
Initial hospitalization was costlier in the HRD-SCT group (55,166 € vs 46,705 €; p = 0.03), mainly due to BP (6920 € vs 2619 €; p < 0.001) and medication (9253 € vs 4262 €; p < 0.001). Among the BP cost, platelet transfusions were costlier in the in the HRD-SCT group (4454 € vs 1416 €; p < 0.001) due to a longer time to reconstitute platelets counts after HRD-SCT [21] . Among the medication costs, GVHD prophylaxy (during the initial hospitalization until GVHD or discharge) was costlier in the HRD-SCT group (1300 € vs 692 €; p < 0.001). Conversely, the pretransplantation phase was less costly for the HRD-SCT group (5294 € vs 43,380 €; p < 0.001), mainly due to GP cost decrease (3857 € vs 41,977 €; p < 0.001). The followup phase, including the treatment of relapse was less costly for the HRD-SCT group (37,844 € vs 62,139 €; p = 0.006) ( Table 2) . Consequently, pre-transplantation costs, initial hospitalization costs, and follow-up costs accounted for 5.4%, 56.1%, and 38.5% of the average total discounted cost in HRD-SCT vs 28.7%, 30.3%, and 41% in UD-SCT, respectively. Costs from transplant up to 1 year after transplant accounted for 88% of total measured costs in both procedures.
Length of stay in the initial hospitalization phase had a mean of 45 (16) 
Cost-effectiveness
ICERs were −148,485 € per life year gained with a 95% confidence region varying from −1,265,550 € to −64,368 € per life year gained and −140,825 € per life year without progression gained with a 95% confidence region varying from −2,859,250 € to −56,528 € per life year without progression gained (Table 3) .
Taking sampling fluctuations into account, the innovative procedure has a lower cost and higher effectiveness in 98% of simulations made (Fig. 3) . Thus, based on this data set, the innovative procedure dominated the reference procedure in cost-effectiveness settings.
Acceptability curves are not shown here as they were constant around 100%.
The univariate sensitivity analyses showed GP costs, full hospitalization costs in the non-ICU or in ICU ward, and Data are presented with n (%) unless otherwise indicated N frequency, NS nonsignificant (p > 0.05); CMV cytomegalovirus; AML acute myeloid leukemia; ALL acute lymphoid leukemia; MDS myelodysplastic syndrome; MPD myeloproliferative disorders; HL Hodgkin lymphoma; NHL non-Hodgkin lymphoma; CLL chronic lymphocytic leukemia; MM multiple myeloma; CML chronic myeloid leukemia; CR complete remission; HCT-CI hematopoietic cell transplantation specific comorbidity index; PBSC peripheral blood stem cells; BM bone marrow; NMAC non-myelo-ablative conditioning; RIC reduce intensity conditioning; NA not applicable a HCT-CI was available for 58 patients intravenous micafungin consumption as major cost drivers. HRD-SCT was dominant compared with UD-SCT in every tested hypothesis (Fig. 4) .
Discussion
Our study showed that HRD-SCT, when applied to adults with hematological malignancies and older than 55, was dominant in cost-effectiveness settings when compared with UD-SCT. Indeed, HRD-SCT was around 53,000 € less expensive, including relapse costs (50,000 excluding relapse costs), which represented a 35% decrease (36% excluding relapse costs) compared with UD-SCT, and allowed a 4 months higher OS and PFS. The ICERs were around −148,500 € per life year gained and around −141,000 € per life year without progression gained.
The cost gap between the two procedures was explained by a pre-transplantation and a follow-up phase more expensive in UD-SCT.
At pre-transplantation phase, GP is responsible for most of the gap with a 38,086 € difference between the two procedures. These costs included, in UD-SCT alone, UD sample and grafts transport, canceling and inscription's fee on register, and postponing fee. Those factors have been previously identified as additional costs in children allo-HSCT [42] .
During the follow-up phase, full non-ICU hospitalization seemed responsible for most of UD-SCT extra cost (+20,790 €). However, no statistical significance was found regarding this factor in our study, likely due to a lack of statistical power.
This extra cost could partly be explained by more side effects and relapse in this group. Indeed, Blaise et al. [21] showed a PFS without severe-GVHD-c less important in UD-SCT vs HRD-SCT (31% vs 67%; p = 0.02). These findings were confirmed by other studies [14] [15] [16] .
On the contrary, initial hospitalization costs were higher in HRD-SCT (+9312 € by patient) without offsetting the extra costs from the two other phases. This extra cost was explained by a higher BP consumption (+4301 € by patient) and a higher expensive medication consumption (+4990 € by patient). Prophylaxis and treatment of infection with intravenous micafungin especially, accounted for 3310 € in cost differences between the two procedures (data not presented in the article).
To our knowledge, our study is the first to perform an economic evaluation of HRD-SCT in older adults. Thus, comparison with the current international literature is challenging. Moreover, considering UD-SCT economic evaluation, the cost perimeter and sources, time horizon and studied population vary greatly among studies [3, 43] . Cost variations across healthcare systems are also a major issue that make comparison more difficult [44] .
Matthes-Martin et al. [29] found, in a study conducted in Austria with children suffering from malignant and nonmalignant hematologic disorders, a median cost for HRD-SCT and UD-SCT of 149,295 € and 134,849 € with a median follow-up of 4.5 years, respectively. UD-SCT and HRD-SCT were associated with higher costs compared with MRD-SCT, with other factors being equal (+41,119 €; p = 0.04 and +63,467 €; p < 0.001, respectively). This study's raw data are not consistent with our findings, as the median cost in our study is higher in UD-SCT than in HRD-SCT (138,344 € vs 87,784 €). Nevertheless these costs cannot be compared properly due to the difference in follow-up (2 years vs 4.5 years) and a pediatric population, which increase costs of allo-HSCT [45] .
Van Agthoven et al. [46] performed a cost analysis of UD-SCT in the Netherlands between 1994 and 1999. Including GP and follow-up cost the authors obtained a total cost of 151,754 € for UD-SCT. Accounting for 1998-2014 healthcare costs inflation in Europe, which was 0.9% yearly [47] , this cost was found slightly higher than our estimation (175,145 € vs 151,373 €). However as previously noted, these costs remain healthcare system dependent, making comparisons difficult. Evolution in allo-HSCT settings between 1998 and 2014 may have decreased its costs, which can partly explain this difference. For instance, the use of reduced intensity conditioning (RIC) has increased in latter decades at the expense of myelo-ablative conditioning, and studies showed that transplants with RIC have lower costs [3, 48] .
Our study was retrospective and performed in a single center, which could lead to some limitations. First, patients in the HRD group were younger than in the UD group (61 vs 64, p = 0.01) suggesting a selection bias on comorbidity and a possible lower cost for this group. Nevertheless, disease risk index and hematopoietic cell transplant-specific comorbidity index [49, 50] were comparable in both groups, which limits the selection bias effect. Another difference between groups was the type of conditioning regimen. In Table 2 HRD-SCT and UD-SCT discounted costs by patient from transplant up to 2 years in € the HRD-SCT group, 66% of the patients received NMAC and 34% RIC, whereas in the UD-SCT group 100% of the patients received RIC. However, we demonstrated in a previous economic evaluation associated with a randomized trial that including treatment of relapse cost, the cost difference initially observed in favor of the NMAC group disappeared [51] . Furthermore, especially for the follow-up phase, costs completeness is based on information available in patient's electronic records. Thus, follow-up costs could be underestimated. For example, if a patient lived far from the transplantation center, it may be possible that several hospital admission related to the transplantation occurred in another hospital. Thus, these costs may not have been thoroughly accounted for. However, around 75% of transplant costs occurred in the pre-transplantation or initial hospitalization phase [43] , which can only occur in transplantation center, which therefore limited the impact on transplantation total costs.
A high cost variation was also found, as total allo-HSCT cost varied from 67,538 € to 398,955 € in UD-SCT and from 56,111 € to 242,729 € in HRD-SCT. In initial hospitalization phase, this could be explained by variations in the transplantation unit length of stay. Indeed, in HRD-SCT initial hospital length of stay varied from 16 to 106 days and from 20 to 109 days in UD-SCT. Medication and BP consumption contributed to this variation. In the pretransplantation phase, multiple conditioning regimens in HRD-SCT were also associated with increased variation (Table 1) .
Despite these biases, sensitivity analyses confirmed the cost-effectiveness dominance of HRD-SCT compared with UD-SCT in our analysis. Analysis accounting for sampling fluctuations uncertainty also supports HRD-SCT dominance, as 98% of the simulations were located in the southeast part of the cost-effectiveness plan.
In this study, effectiveness was assessed with OS and PFS, which did not account for patients' quality of life. It is likely that patients undergoing HRD-SCT had a better longterm quality of life compared with UD-SCT, because of fewer severe-GVHD-c [21] . Nevertheless, this remains to be confirmed in further studies. Our study was associated with a "real world" practice observation, with data offering good external validity characteristics (i.e., the way to represent the real world data). Internal validity of data needs to be improved in the frame of a prospective randomized trial. Such a trial is actually ongoing in our hospital, with Pr Didier Blaise as principal investigator (Mudelderly). An economic evaluation including patients' quality of life measurement is associated with this trial.
In a restrained economic environment, the availability of highly specialized care with high costs is a major issue. Early economic evaluation on the diffusion pathway of clinical innovation highlights the decision process of the opinion leaders, even if further evaluations are needed. If results shown by our study are confirmed, HRD-SCT in adults with hematological malignancies could significantly reduce the costs of allo-HSCT with equivalent or better survival and better donor availability. Prospective studies should be further conducted in order to confirm these results and addressing quality of life assessment issue.
